Challenges Associated with Addressing Counterfeit Medicines in Nigeria: An Exploration of Pharmacists’ Knowledge, Practices, and Perceptions

References

• Isles M. What’s in a word? Falsified/counterfeit/fake medicines – the definitions debate. Med Access @ Point Care. 2017;1(1):e40–e48. doi:10.5301/maapoc.0000008
   Google Scholar
• Shrivastava SR, Shrivastava PS, Ramasamy J. Public health measures to fight counterfeit medicine. Int J Prev Med. 2013;5(3):370.
   Google Scholar
• World Health Organization (WHO). A study on the public health and socioeconomic impact of substandard and falsified medical products. Available from: https://apps.who.int/iris/handle/10665/331690. Accessed May 22, 2022.
   Google Scholar
• Erhun WO, Babalola OO, Erhun MO. Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J Health Popul Dev Count. 2001;4(2):23–34.
   Google Scholar
• Atholl J, David WH. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243. doi:10.1111/bcp.12298
   PubMed Web of Science ®Google Scholar
• Ekeh CM, Adekoya HO. Awareness and adoption of drug mobile authentication service: a conscious approach in eradication of fake and counterfeit drugs in Nigeria. KIU J Soc Sci. 2021;7(1):43–51.
   Google Scholar
• Osibo OO. Faking and counterfeiting of drugs. West Afr J Pharm. 1998;12:53–57.
   Google Scholar
• Glass BD. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med. 2014;5:11–22. doi:10.2147/RRTM.S39354
   PubMedGoogle Scholar
• Blackstone EA, Fuhr JJP, Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits. 2014;7(4):216–224.
   PubMedGoogle Scholar
• Delepierre A, Gayot A, Carpentier A. Update on counterfeit antibiotics worldwide; public health risks. Med Mal Infect. 2012;42(6):247–255. doi:10.1016/j.medmal.2012.04.007
   PubMed Web of Science ®Google Scholar
• Jha AK, Prasopa-Plaizier N, Larizgoitia IA, Bates DW. Patient safety research: an overview of the global evidence. BMJ Qual Saf. 2010;19(1):42–47. doi:10.1136/qshc.2008.029165
   Web of Science ®Google Scholar
• Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2(4):100. doi:10.1371/journal.pmed.0020100
   PubMed Web of Science ®Google Scholar
• Okereke M, Anukwu I, Solarin S, Ohuabunwa MS. Combatting substandard counterfeit medicines in the Nigerian drug market: how industrial pharmacists can rise up to the challenge. commentary. Pharm Based Pract Pract Based Res. 2021;12(3):15. doi:10.24926/iip.v12i3.4233
   Google Scholar
• Akunyili D. The challenges faced by NAFDAC in the national regulatory process as it relates to essential drugs for prevention of maternal and newborn deaths in Nigeria. Trop J Obstet Gynaecol. 2010;27(1):81–87.
   Google Scholar
• Ogbonna BO, Ilika AL, Nwabueze SA. National drug policy in Nigeria, 1985–2015. World J Pharm Res. 2015;4(6):248–264.
   Google Scholar
• Erhun WO. Maintaining qualitative pharmacy practice in a depressed economy. Niger J Pharm. 1996;27(2/3):9–13.
   Google Scholar
• Obinna C. Nigeria losing war against fake drugs. Vanguard Nigeria; 2019. Available from: https://www.vanguardngr.com/2019/03/nigeria-losing-war-against-fake-drugs-experts/. Accessed March 9, 2022..
   Google Scholar
• Garuba HA, Kohler JC, Huisman MA. Transparency in Nigerian public pharmaceutical sector: perceptions from policymakers. Glob Health. 2009;5(1):1–13. doi:10.1186/1744-8603-5-14
   PubMed Web of Science ®Google Scholar
• Akinyadenu O. Counterfeit drugs in Nigeria: a threat to public health. Afr J Pharm Pharmacol. 2013;7(36):2571–2576. doi:10.5897/AJPP12.343
   Google Scholar
• Law E, Youmans SL. Combating counterfeit medications: the California pharmacist perspective. J Pharm Prac. 2011;24:114–121. doi:10.1177/0897190010380745
   PubMedGoogle Scholar
• Taleb YA, Madadha RA. Pharmacists’ awareness about counterfeit medications in Jordan. J Roy Med Serv. 2013;20:57–70. doi:10.12816/000007
   Google Scholar
• Alfadl AA, Hassali MA, Ibrahim MI. Counterfeit drug demand: perceptions of policy makers and community pharmacists in Sudan. Res Social Adm Pharm. 2013;9:302–310. doi:10.1016/j.sapharm.2012.05.002
   PubMed Web of Science ®Google Scholar
• Al-Worafi YM. Pharmacy practice and its challenges in Yemen. Australas Med J. 2014;7:17. doi:10.4066/AMJ.2014.1890
   PubMedGoogle Scholar
• Sholy L, Gard P, Williams S, MacAdam A. Pharmacist awareness and views towards counterfeit medicine in Lebanon. Int J Pharm Pract. 2018;26(3):273–280. doi:10.1111/ijpp.12388
   PubMed Web of Science ®Google Scholar
• Bashir A, Galal S, Ramadan A, Wahdan A, El-Khordangui L. Community pharmacists’ perceptions, awareness and practices regarding counterfeit medicines: a cross-sectional survey in Alexandria, Egypt. East Mediterr Health J. 2020;26(5):556–564. doi:10.26719/emhj.19.058
   PubMed Web of Science ®Google Scholar
• Yakubu O An analysis of loopholes in the pharmaceutical supply chain, and methods for improving control of counterfeit drugs in Nigeria [Research Thesis]. Dublin: Griffith College; 2020. Available from: https://go.griffith.ie/446/1/3280_Ojima_Precious_Yakubu_Ojima_Precious_Yakubu_Final_Dissertation_Copy_3970_607779346.pdf. Accessed February 10, 2022.
   Google Scholar
• Parsons VL. Stratified sampling. Wiley StatsRef. 2014;1–11. doi:10.1002/9781118445112.stat05999.pub2
   Google Scholar
• Alfa J, Adigwe OP. Rational use of medicines in Nigeria: a critical review. J Biol Agric Healthc. 2014;4:89–99.
   Google Scholar
• Toklu HZ, Mensah E. Why do we need pharmacists in pharmacovigilance systems? Online J Public Health Inform. 2016;8(2). doi:10.5210/ojphi.v8i2.6802
   PubMedGoogle Scholar
• Akunyili D. Strategies employed in combatting drug counterfeiting in Nigeria. A paper presented at: the WHO workshop in collaboration with Italian medicines agency and the international federation of pharmaceutical manufacturers and associations. Rome, Italy. Feb 15th–18th; 2006.
   Google Scholar
• World Health Organization. WHO global surveillance and monitoring system for substandard and falsified medical products; 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf. Accessed October 20, 2022.
   Google Scholar
• Odili VU, Osemwenkha S, Eke EU, Okeri HA. Identification of counterfeit drugs by community pharmacists in Lagos State. Trop J Pharm Res. 2006;5(1):545–550. doi:10.4314/tjpr.v5i1.14631
   Google Scholar
• Mhando L, Jande MB, Liwa A, Mwita S, Marwa KJ. Public awareness and identification of counterfeit drugs in Tanzania: a view on antimalarial drugs. Adv Public Health. 2016;1–8. doi:10.1155/2016/6254157
   Google Scholar
• Aminu NA, Gwarzo MS. The eminent threats of counterfeit drugs to quality health care delivery in Africa: updates on consequences and way forward. Asian J Pharma Clin Res. 2017;10(7):82–86. doi:10.22159/ajpcr.2017.v10i7.18384
   Google Scholar
• Sipahi H, Peltekoglu K, Sencan N. Adverse effects of counterfeit drugs on public health. J Fac Pharm Ist Univ. 2014;44(1):89–99.
   Google Scholar
• Shipalana P, Matema T, Van Der Westhuizen H. Counterfeit pharmaceuticals: a major threat to public health. South African Institute of international affairs; 2020. Available from https://www.jstor.org/stable/resrep29593. Accessed July 3, 2022.
   Google Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543. doi:10.1093/ajhp/47.3.533
   PubMedGoogle Scholar
• Esposito M. Strategies to combat counterfeit drugs and other pharma supply chain threats. Guest column; 2018. Available from: https://www.pharmaceuticalonline.com/doc/strategies-to-combat-counterfeit-drugs-and-other-pharma-supply-chain-threats-0001. Accessed May 4, 2022.
   Google Scholar
• Akande-Sholabi W, Adebisi YA. The impact of COVID-19 pandemic on medicine security in Africa: Nigeria as a case study. The Pan African Medical Journal. 2020;35(Suppl2). doi:10.11604/pamj.supp.2020.35.2.23671
   PubMed Web of Science ®Google Scholar
• Adigwe OP. Stakeholders’ perspective of role of policy and legislation in achieving medicines’ security. Int J World Pol Dev Stud. 2020;6(6):66–73. doi:10.32861/ijwpds.66.66.73
   Google Scholar
• Ekpenyong A, Udoh A, Kpokiri E, Bates I. An analysis of pharmacy workforce capacity in Nigeria. J Pharm Policy Pract. 2018;11(1):1–9. doi:10.1186/s40545-018-0147-9
   PubMedGoogle Scholar